10-Q: C4 Therapeutics Secures $117M, Extends Runway to 2028

C4 Therapeutics reported increased Q3 2025 net losses but bolstered its cash position with a $117 million underwritten offering, extending its operational runway to the end of 2028.

Summary

• Net loss for the nine months ended September 30, 2025, increased to $84.5 million from $70.7 million in the prior year.
• Revenue from collaboration agreements decreased to $24.9 million for the nine months ended September 30, 2025, from $30.4 million in the same period last year, primarily due to lower Biogen and Betta collaboration activity, partially offset by increased Merck, MKDG, and Roche revenue.
• Cash, cash equivalents, and marketable securities totaled $199.8 million as of September 30, 2025.
• Subsequent to the quarter, C4 Therapeutics completed an underwritten offering in October 2025, raising approximately $117.0 million in net proceeds, extending its operational runway to the end of 2028.
• An impairment charge of $10.7 million was recognized for long-lived assets in Q3 2025 due to a new sublease agreement.
• Cemsidomide, a lead product candidate, showed compelling anti-myeloma activity in Phase 1 Multiple Myeloma data, and the company plans to initiate a Phase 1b trial with elranatamab (Pfizer collaboration) and a registrational Phase 2 trial in MM in 2026.
• The company decided not to advance CFT1946 beyond its Phase 1 trial.
• The collaboration agreement with Merck for degrader-antibody conjugates (DACs) was terminated in September 2025, effective late November 2025.

Sentiment

Score: 4

Explanation: While the company reported increased net losses and a decrease in collaboration revenue, the successful $117 million capital raise (subsequent to the quarter end) significantly extends its cash runway to the end of 2028, which is a critical positive for a clinical-stage biotech. The termination of the Merck collaboration and the decision to halt CFT1946 development are negatives, but the advancement of cemsidomide into later-stage trials provides a clear path forward for its lead candidate. The overall sentiment is cautious due to ongoing losses and pipeline adjustments, but the strengthened financial position offers a degree of stability.

Positives

• Successfully completed an underwritten offering in October 2025, raising approximately $117.0 million in net proceeds.
• Extended the cash runway to the end of 2028, providing longer financial stability.
• Cemsidomide Phase 1 data in Multiple Myeloma demonstrated a well-tolerated profile, robust IKZF1/3 degradation, T-cell activation, and compelling anti-myeloma activity.
• Plans to initiate the next phase of cemsidomide development in Multiple Myeloma in 2026, including a Phase 1b trial with Pfizer's elranatamab and a registrational Phase 2 trial.
• Achieved a $1.0 million discovery milestone for one of the active collaboration targets under the MKDG Agreement in April 2025.
• Achieved a $4.0 million milestone under the Roche Agreement in March 2025 for two active collaboration targets progressing to the lead series identification achievement phase.
• Earned a $2.0 million milestone from Biogen in September 2025 after BIIB142 advanced into the clinic.
• Betta Pharma initiated a Phase 1 clinical trial for CFT8919 in NSCLC patients in Greater China in November 2024.
• Net cash provided by investing activities for the nine months ended September 30, 2025, was $72.1 million, a significant improvement from a $64.9 million usage in the prior year.

Negatives

• Net loss increased to $32.2 million for the three months ended September 30, 2025, from $24.7 million in the prior year.
• Net loss for the nine months ended September 30, 2025, increased to $84.5 million from $70.7 million in the prior year.
• Revenue from collaboration agreements decreased by $4.1 million for the three months and $5.5 million for the nine months ended September 30, 2025, compared to the prior year periods.
• Incurred a $10.7 million impairment charge for long-lived assets in Q3 2025 due to a new sublease agreement.
• Decision not to advance CFT1946 beyond its Phase 1 trial, indicating a pipeline setback.
• The collaboration agreement with Merck for degrader-antibody conjugates (DACs) was terminated in September 2025.
• Net cash used in operating activities increased to $76.5 million for the nine months ended September 30, 2025, from $47.2 million in the prior year.
• Interest and other income, net, decreased by $1.3 million for the three months and $3.6 million for the nine months ended September 30, 2025, due to reduced invested balances and lower interest rates.

Risks

• The company is a clinical-stage biopharmaceutical company with a history of significant losses and expects to incur losses for the foreseeable future, potentially never achieving profitability.
• Substantial additional funding will be needed to pursue business objectives and continue operations; inability to raise capital could lead to delays, reductions, or termination of research/development programs or commercialization efforts.
• The TORPEDO platform approach to discovery and development is unproven, making it difficult to predict time, cost, and likelihood of success.
• Failure to successfully develop, obtain regulatory approval for, and/or commercialize product candidates, or significant delays, could harm the business.
• Uncertainty regarding timely completion or outcome of preclinical testing and clinical trials; preclinical results may not predict clinical trial results, and early-stage clinical trial results may not predict later-stage results.
• Preclinical studies and clinical trials may fail to adequately demonstrate safety and efficacy, preventing or delaying development, regulatory approval, and commercialization.
• Potential failure to realize full benefits from existing or future collaboration arrangements (Roche, Betta Pharma, MKDG).
• Substantial competition from other companies developing protein degradation therapies and traditional therapeutic modalities.
• Reliance on third parties for manufacturing product candidates increases the risk of insufficient quantities, unacceptable cost, or quality, leading to delays.
• Inability to obtain required marketing approvals, commercialize, manufacture, obtain/maintain patent protection, or gain market acceptance, or significant delays, would materially harm the business.
• Inability to obtain and maintain broad or enforceable patent protection could allow competitors to develop similar products, impairing commercialization.
• Future sales and issuances of common stock or rights to purchase common stock, and exercise of outstanding warrants, would result in additional dilution and could cause stock price to fall.
• Outstanding Class A and Class B Warrants may not be exercised, meaning the company may not receive anticipated additional funds.
• The market opportunities for product candidates may be relatively small, and estimates of target patient populations may be inaccurate.
• Even if approved, products may fail to achieve market acceptance by physicians, patients, and payors.
• No current marketing and sales organization or experience in marketing products; inability to establish capabilities or secure third-party agreements could hinder product revenue.
• Products may become subject to unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives.
• Product liability lawsuits could lead to substantial liabilities and limit commercialization.
• Weakening patent laws and enforcement by courts may impact the ability to protect markets.
• Potential claims by third parties of intellectual property misappropriation or ownership of company IP.
• Dependence on key personnel; inability to attract and retain highly qualified personnel could hinder business strategy.
• Internal computer systems or those of third parties may fail or suffer security breaches, disrupting development and harming reputation.
• Employees, contractors, and consultants may engage in misconduct or improper activities.
• Business disruptions (natural disasters, global conflicts, unstable market conditions) could adversely affect business, financial condition, and stock price.
• Adverse developments in the financial services industry could affect funding access.

Future Outlook

The company anticipates continued significant expenses and operating losses as it advances preclinical programs and product candidates through clinical development. It expects to initiate the next phase of cemsidomide development in Multiple Myeloma in 2026, including a Phase 1b trial with Pfizer's elranatamab and a registrational Phase 2 trial with dexamethasone. The company believes its current cash, cash equivalents, and marketable securities, combined with the $117.0 million net proceeds from the October 2025 underwritten offering, will be sufficient to fund operations until the end of 2028. However, it will need substantial additional funding to complete development and commercialization of its product candidates.

Management Comments

• We are a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation, or TPD, science to create a new generation of small-molecule medicines that transform patients lives.
• We are prioritizing cemsidomide development in MM.
• We expect to initiate the next phase of cemsidomide development in MM in 2026, including a Phase 1b trial in combination with elranatamab that we will conduct pursuant to the Pfizer Agreement, and a registrational Phase 2 trial with cemsidomide in combination with dexamethasone.
• We have made the decision not to advance CFT1946 beyond the Phase 1 trial.
• We believe that together these funds [cash, cash equivalents, marketable securities, and October 2025 offering proceeds] will be sufficient to fund our planned operating expenses to end of 2028.

Industry Context

The biopharmaceutical industry is highly competitive and characterized by rapid technological advancements. Targeted protein degradation (TPD) is an an emerging therapeutic modality attracting significant interest and investment from numerous biotechnology and pharmaceutical companies. C4 Therapeutics operates within this competitive landscape, leveraging its proprietary TORPEDO platform. The termination of the Merck collaboration highlights the inherent risks and evolving nature of partnerships in early-stage drug development. The company's focus on oncology, particularly multiple myeloma and non-small cell lung cancer, places it in a crowded but high-value therapeutic area, where innovation in TPD could offer significant advantages over traditional therapies, especially in overcoming drug resistance. The recent capital raise is a common strategy for clinical-stage biotechs to extend their runway and fund expensive R&D.

Comparison to Industry Standards

• The decision to discontinue CFT1946 development beyond Phase 1, despite initial signs of anti-tumor activity, is a common practice in the highly selective and risk-averse biopharmaceutical industry, where companies often prune their pipelines to focus resources on candidates with higher potential or clearer development paths.
• The termination of the Merck collaboration, while a setback, is not uncommon in early-stage drug development partnerships, where programs may be re-evaluated based on emerging data, strategic shifts, or competitive landscape changes.
• The underwritten offering and warrant issuance are standard capital-raising mechanisms for clinical-stage biotechnology companies, reflecting the significant capital requirements for drug development. The terms, including the exercise price of warrants relative to the current stock price, are typical for companies seeking to extend their cash runway.
• The company's cash runway extension to the end of 2028, following the capital raise, is a positive indicator of financial stability, often benchmarked against peers to assess operational longevity without immediate need for further dilution.
• The advancement of cemsidomide into registrational Phase 2 trials and a Phase 1b combination trial, particularly with a major pharmaceutical partner like Pfizer, aligns with industry standards for progressing promising oncology candidates.

Corporate Governance

Legal Proceedings

• Not currently party to any material legal proceedings.

Related Party Transactions

• Betta Investment (an affiliate of Betta Pharma) purchased 5,567,928 shares of common stock for approximately $25.0 million on January 4, 2024.
• Following a subsequent offering, Betta Investment is no longer considered a related party based on its current holdings of 4,874,550 shares.

Stakeholder Impact

• Shareholders: Experienced dilution from the recent underwritten offering and face potential future dilution from warrant exercises. Increased net losses could negatively impact share price, but the extended cash runway provides critical financial stability.
• Employees: A restructuring plan in January 2024 resulted in a 30% workforce reduction. Stock-based compensation is a key incentive, but its value is tied to stock price volatility.
• Customers (future): Potential for new targeted protein degradation therapies for multiple myeloma and non-small cell lung cancer.
• Collaboration Partners (Pfizer, Roche, MKDG, Betta Pharma): Ongoing collaborations continue, with milestones achieved and new trials planned (Pfizer). The Merck termination impacts that specific partnership.

Next Steps

• Initiate a Phase 1b trial for cemsidomide in combination with elranatamab in Multiple Myeloma in 2026.
• Initiate a registrational Phase 2 trial for cemsidomide in combination with dexamethasone in Multiple Myeloma in 2026.
• Continue to advance other product candidates into preclinical and clinical development.
• Continue to invest in the proprietary TORPEDO platform.
• Seek marketing approvals for any product candidates that successfully complete clinical trials.
• Potentially establish a sales, marketing, and distribution infrastructure for approved products.
• Advance, expand, maintain, and protect the intellectual property portfolio.
• Hire additional clinical, regulatory, quality, and scientific personnel.
• Add operational, financial, and management information systems and personnel.

Key Dates

Recommendation

While the company reported increased net losses and pipeline adjustments (CFT1946 discontinuation, Merck termination), the successful $117 million capital raise significantly extends the cash runway to the end of 2028, providing crucial financial stability for a clinical-stage biotech. The advancement of cemsidomide into later-stage trials, including a registrational Phase 2, is a positive development for its lead candidate. However, the company remains in early development, faces high competition, and has not yet achieved profitability. The dilution from the recent offering and the uncertainty of warrant exercises are factors to consider. Given the mixed bag of financial performance, pipeline adjustments, and a strengthened but still early-stage outlook, a 'hold' recommendation is appropriate, awaiting further clinical data and clearer paths to commercialization.

Keywords

Targeted Protein Degradation, TPD, Cemsidomide, Multiple Myeloma, Non-Hodgkin Lymphoma, IKZF1/3 degrader, CFT1946, BRAF V600 mutant, Melanoma, Colorectal Cancer, CFT8919, EGFR L858R mutation, NSCLC, BiDAC, MonoDAC, TORPEDO platform, Biopharmaceutical, Clinical-stage, SEC Filing, 10-Q, Underwritten Offering, Capital Raise, Collaboration Agreements, Pfizer, Roche, Betta Pharma, MKDG, Orphan Drug Designation